Lite Strategy/$LITS
1D1W1MYTD1Y5YMAX
Capital at risk
About Lite Strategy
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
- Ticker
- $LITS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4
- Headquarters
- San Diego, United States
- Website
- www.litestrategy.com
Lite Strategy Metrics
BasicAdvanced
$38M
-
-$2.21
0.04
-
Price and volume
Market cap
$38M
Beta
0.04
52-week high
$2.97
52-week low
$0.69
Average daily volume
320K
Financial strength
Current ratio
11.528
Quick ratio
7.924
Profitability
EBITDA (TTM)
-17.126
Management effectiveness
Return on assets (TTM)
-27.69%
Return on equity (TTM)
-159.26%
Valuation
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-2.991
Free cash flow yield (TTM)
-33.43%
Free cash flow per share (TTM)
-0.378
Growth
Earnings per share change (TTM)
-53.59%
3-year earnings per share growth (CAGR)
-27.07%
10-year earnings per share growth (CAGR)
-15.65%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.